Page 14 of 20

IM29.{24,26} | Impaired Physicians and Research Consent — SDL Guide (Part 2)

Vulnerable Populations, Illiterate Participants, and Special Consent Scenarios

The consent process described above applies to a competent, literate adult making an autonomous, fully informed decision. Real clinical research frequently involves participants who do not fit this straightforward profile — and the additional protections required in these circumstances are a key assessment point in the NMC IM29.26 competency. The ICMR Guidelines 2017/2023 and the Indian GCP specify detailed additional safeguards for vulnerable populations, defined as individuals who have reduced capacity for autonomous decision-making due to power imbalances, cognitive limitations, institutional dependency, or socio-economic circumstances.

The categories of vulnerability recognised in ICMR Guidelines with their specific additional requirements are:

Children (minors under 18 years): Consent is obtained from the parent or legal guardian (called permission in research ethics terminology). Assent — the child's own agreement to participate, in age-appropriate terms — must also be sought from any child aged 7 years or older who is capable of understanding, and from all adolescents. A child's dissent (explicit refusal) overrides parental permission in research not offering direct benefit. The distinction is clinically important: parental permission alone is insufficient for research involving minors who are capable of expressing a view.

Illiterate adults: As discussed in the companion SDL on medical ethics, illiteracy does not remove the right to research participation — it requires a procedurally modified consent. The ICMR-specified procedure for an illiterate adult participant: (a) the Participant Information Sheet must be read aloud in the participant's language, with adequate explanation; (b) an impartial witness — independent of the research team and the participant's family — must be present throughout the consent process; (c) the participant's signature is replaced by their left thumb impression (or other identifiable mark); (d) the impartial witness signs the consent form, attesting that the information was given and the participant appeared to understand and consent voluntarily; (e) the consent form must clearly state that the participant is illiterate and the witness name and relationship must be documented.

Patients enrolled in research by their treating clinician: The therapeutic relationship creates a power differential — patients may feel unable to refuse participation when their doctor asks them to enrol. The ICMR Guidelines require that the consent process explicitly address this: the participant must be clearly told that declining to participate will not in any way affect the quality or availability of their clinical care, and this assurance should ideally be provided by someone other than the treating clinician.

Psychiatric patients: Capacity assessment is mandatory before enrolling any patient with a psychiatric diagnosis into research. An acute psychiatric episode (psychosis, severe depression) may temporarily remove the ability to provide valid consent. Research on patients who are compulsorily admitted under the MHCA 2017 is permitted only with approval from the treating team, the participant's nominated representative, and the IEC — and only for research on the mental health condition itself, not for unrelated studies.

Prisoners and institutional residents: Participation must be genuinely voluntary — coercion from the institutional authority or offers of benefits that constitute undue inducement (e.g., parole consideration) are prohibited. Research in these settings requires specific IEC review and approval.

Emergency research (when consent cannot be obtained): Research involving emergency care patients (e.g., a trial of a novel CPR intervention in cardiac arrest) may proceed without prospective consent under a waiver of consent approved by the IEC, provided: (a) the research could not be conducted in non-emergency populations; (b) the intervention poses minimal additional risk beyond standard emergency care; (c) consent will be obtained retrospectively from the participant or their legally authorised representative as soon as possible; and (d) the IEC has specifically approved the waiver.

The practical simulation of research consent (IM29.26) — the component tested in the OSCE — requires the student to demonstrate the full ten-step consent process described above, adapted to the specific participant scenario presented. Key performance indicators that OSCE assessors evaluate:

OSCE criterion	Performance standard
Introduces self and role	Name, designation, and affiliation with study team stated clearly
Explains research vs treatment distinction	Explicitly corrects therapeutic misconception if present
Covers all 10 ICMR elements	Each element addressed in plain language
Assesses comprehension	Asks participant to re-explain in own words (not just 'Do you understand?')
Confirms voluntariness	Explicitly states right to refuse and right to withdraw
Handles illiterate participant correctly	Thumb impression + impartial witness procedure demonstrated
Responds to a refusal	Accepts refusal graciously; confirms no impact on clinical care
Documentation	Consent form elements correctly completed with date/time/witness

Self-Assessment: Integrating Impaired Physician Response and Research Consent

You have now covered the full scope of IM29.24 and IM29.26 — the definition and causes of physician impairment, the ethical and legal frameworks governing the response to an impaired colleague, the regulatory foundation and procedural elements of research consent, and the specific adaptations required for vulnerable populations including illiterate adults and children. The self-assessment below consolidates this through three integrative scenarios that combine both topics and require you to navigate the professional obligations, the relevant regulatory framework, and the practical communication skills.

For each scenario, identify the applicable regulatory framework (NMC Act 2020, MHCA 2017, ICMR Guidelines 2017/2023, GCP, Declaration of Helsinki, or a combination), state the ethical principles engaged, and describe the specific action you would take.

Scenario A — The impaired colleague with mental health condition:
Dr. Sunita, a third-year psychiatry resident, discloses to you in confidence that she has been diagnosed with major depressive disorder for the past six months, is on antidepressants, and is seeing a psychiatrist fortnightly. She is managing her workload and her department head is unaware. She asks you not to tell anyone. She is not showing any signs of clinical impairment. What are your ethical and legal obligations?

Analysis: This scenario tests the intersection of IM29.24 and MHCA 2017. The MHCA 2017 prohibits discrimination on grounds of mental health condition and protects individuals' right to seek and receive mental health treatment without mandatory reporting to their employer. More importantly, IM29.24 is triggered by impairment affecting patient care — not by diagnosis. Dr. Sunita is managing her condition, is under appropriate professional care, and is showing no signs of clinical impairment. Your obligations here are: (a) maintain the confidentiality of her disclosure under the professional duty of confidentiality (NMC Code); (b) continue to observe her clinical function — if you subsequently observe signs of impairment, the situation changes; (c) support her emotionally and professionally; (d) do not report to her department head — there is currently no patient safety risk to trigger that obligation. If she were showing signs of impairment, the calculus would change — but depression with treatment and a functioning clinician is not the same as an impaired clinician.

Scenario B — The research consent in a challenging setting:
You are sub-investigator in a study of a new SGLT2 inhibitor for type 2 diabetes with CKD. A potential participant is a 55-year-old woman with limited formal education. Her husband is present and has read the participant information sheet on her behalf. He says she agrees. She has not been spoken to directly. You notice she appears to understand the conversation around her but has not spoken. How do you proceed?

Analysis: This is the proxy-consent-before-patient-speaks scenario — a form of surrogate consent being applied to a potentially competent adult. The correct approach: speak to the participant directly, in her language, using the participant information sheet. Capacity assessment first — she may be fully competent and merely deferential. If she has capacity, her own consent is required; her husband's reading of the PIS does not substitute for direct consent. Explain each ICMR element directly to her, ask her comprehension questions, and ensure her consent is genuinely voluntary — not driven by pressure from her husband or the treating team. If she lacks capacity (confirmed by assessment, not assumed from her silence), the surrogate consent process applies with her husband as nearest relative, and her assent should still be sought for any aspect she can understand.

Therapeutic Consent vs Research Consent in India

Scenario C — Emergency incapacity and waiver of consent in research:
A cardiac arrest study is being conducted in your hospital's emergency department. The protocol has IEC-approved waiver of consent for the initial resuscitation phase (the patient cannot consent during active cardiac arrest). A patient is enrolled under the waiver. She survives and regains capacity 30 minutes after arrival. The research assistant tells you she will be told about the study 'when she feels better — maybe tomorrow.' What is the correct procedure?

Analysis: The IEC-approved waiver of consent for emergency research requires retrospective consent to be obtained 'as soon as possible' — not at clinical convenience. ICMR Guidelines specify that when the participant regains capacity, consent must be sought promptly for continued participation in the study and for use of any data collected during the waiver period. If the patient declines consent retrospectively, the study data from her participation may not be usable (depending on the IEC protocol), and she must be withdrawn from the study immediately. 'Tomorrow when she feels better' is a procedural delay that could be challenged as prolonging non-consented research participation. The correct action: the principal investigator or sub-investigator should visit the patient within the next 1–2 hours (once she is clinically stable and capable), explain the study and the waiver procedure, and obtain prospective consent for continued participation or withdrawal.